Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$673.9MCash, Jun 2026
30moCash Runway (est.)
+55%Share Count, 1 Year
Follow ZBIO by emailGet an email when ZBIO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ZBIO, unsubscribe in one click. Privacy
💊 Upcoming FDA Decisions
PDUFA Date
Drug
Indication
Type
PoA
2027-05-27
—
IgG4-RD accepted by FDA
BLA
64%
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area and cash runway. Not investment advice. See the full PDUFA calendar →
📣 What ZBIO Says Is Next
fourth quarter of 2026 · “Zenas expects to report topline results from a Phase 2 trial for obexelimab in systemic lupus erythematosus in the fourth quarter of 2026.”
Company press release, Aug 13, 2026 · SEC filing
in 2027 · “Zenas expects to advance the program into Phase 1 clinical development in 2027.”
Company press release, Aug 13, 2026 · SEC filing
in 2027 · “Upon completion and evaluation of the SAD and MAD study, Zenas plans to initiate a proof-of-concept (POC) trial in North America to evaluate clinical activity and safety in psoriasis patients with results anticipated in 2027.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
ZBIO reported $673.9M in cash and short-term investments (as of Jun 30, 2026) and used about $66.8M/quarter in operations, an estimated runway of 30.3 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZBIO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.